Graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-O-methyltransferase

Journal of Nuclear Medicine

Volumn 38, Issue 10, 1997, Pages 1568-1574

  Holden, J E ^a   Doudet, D ^a   Endres, C J ^a   Chan, G L Y ^a   Morrison, K S ^a   Vingerhoets, F J G ^a   Snow, B J ^a   Pate, B D ^a   Sossi, V ^a   Buckley, K R ^a   Ruth, T J ^a  

^a 1530 Medical Sciences Center ^*

Author keywords

6 fluoro dopa; COMT inhibition; Extended graphical method; PET; Reversible trapping

Indexed keywords

6 FLUORODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; NITECAPONE; TOLCAPONE; TRACER;

ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; INTRAPERITONEAL DRUG ADMINISTRATION; MACACA; MALE; METHYLATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; BENZOPHENONES; BRAIN; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROXYPHENYLALANINE; ENZYME INHIBITORS; FLUORINE RADIOISOTOPES; MACACA FASCICULARIS; MALE; NITROPHENOLS; PENTANONES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 9844233705     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-138.
2. Vingerhoets FJG, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa PET in normal human subjects. J Nucl Med 1994;35:18-24.
3. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with PET. Ann Neurol 1989;26:535-542.
4. Zurcher G, Dingemanse J, DaPrada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New developments in therapy of Parkinson's disease. Rome: John Libbey: 1991:37-43.
5. DaPrada M, Zurcher G, Kettler R, Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. In: Bernardi G, ed. The basal ganglia III. New York: Plenum Press; 1990:723-731.
6. 18F]fluoro-L-dopa in rats, monkeys and humans. Life Sci 1990;47:149-157.
7. 18F]fluoro-dopa in human PET studies. J Cereb Blood Flow Metab 1991;11:898-913.
8. 18F]fluoro-L-dopa and PET: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993;13:43-56.
9. Pate BD, Snow BJ, Hewitt KA, et al. The reproducibility of striatal uptake data obtained with PET and fluorine-18-E-6-fluorodopa tracer in non-human primates. J Nucl Med 1991;32:1246-1251.
10. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
11. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: Generalizations. J Cereb Blood Flow Metab 1985;5: 584-590.
12. Evans B, Harrop R, Heywood D. Engineering developments on the UBC-TRIUMF modified PETT VI positron emission tomograph. IEEE Trans Nucl Sci 1983;NS-30: 707-710.
13. 18F]-fluorodopa. Appl Radiat Isot 1988;39:1203-1206.
14. 18F]L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies. Life Sci 1992;50:309-318.
15. Sossi V, Buckley KR, Snow BJ, et al. Recovery of the human striatal signal in a slice oriented positron emission tomograph. J Nucl Med 1993;34:481-487.
16. Holden JE, Pate BD, Adam MJ, Ruth TJ, Calne DB. Study of the effects of the labeled metabolite 3-O-methyl-6-fluorodopa on the interpretation of 6-fluorodopa kinetics measured with PET [Abstract]. J Nucl Med 1991;32:1007.
17. 18F]fluoro-L-dopa in the rhesus monkey brain. J Cereb Blood flow Metab 1991;11:726-734.
18. 18F]6-fluoro-3-O-methyl-L-dopa in the human brain. J Cereb Blood Flow Metab 1994;14:664-670.
19. Laihinen A, Rinne JO, Rinne UK, et al. Fluorine-18-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 1992;42:199-203.
20. Guttman M, Léger G, Reches A, et al. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 1993;8:298-304.